Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A viral hemorrhagic fever that is caused by the Lassa virus, which is transmitted by contact with infected rodents; it is characterized by fever, headache, malaise, myalgia, and hearing loss.
Features include very common findings: Fever, Increased circulating IgM level, Viremia, and Asthenia and others; and common findings: Muscle weakness, Difficulty swallowing (dysphagia), Nausea and vomiting, and Abdominal pain and others. 27 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 5 | Difficulty swallowing (dysphagia), Nausea and vomiting, Abdominal pain |
Biomarker and diagnostic research for Lassa fever has been reported in the published literature.
Phenotype severity distribution: 5 very common features, 8 common features.
Estimated prevalence: Unknown (Unknown prevalence).
7 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 4 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05868733](https://clinicaltrials.gov/study/NCT05868733) |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 7:12 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Lassa fever
Brain and nerves |
3 |
Difficulty swallowing (dysphagia), Headache, Seizure |
Metabolism | 1 | Fever |
Muscles | 1 | Muscle weakness |
Heart and blood vessels | 1 | Chest pain |
Head and neck | 1 | Facial edema |
Ears | 1 | Hearing loss (hearing impairment) |
Eyes | 1 | Conjunctivitis |
Blood and immune system | 1 | Abnormal bleeding tendency (abnormal bleeding) |
Lungs and breathing | 1 | Dyspnea |
Bones and joints | 1 | Arthralgia |
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa |
PHASE2 |
International AIDS Vaccine Initiative |
RECRUITING |
[NCT06212336](https://clinicaltrials.gov/study/NCT06212336) | ISTH/ANRS 0409s INTEGRATE Lassa Fever Study | PHASE2 | Irrua Specialist Teaching Hospital | RECRUITING |
[NCT06546709](https://clinicaltrials.gov/study/NCT06546709) | DMID 23-0015; Lassa Fever CVD 1000 | PHASE1 | Wilbur Chen, MD, MS | ACTIVE_NOT_RECRUITING |
[NCT03655561](https://clinicaltrials.gov/study/NCT03655561) | Lassa Fever Clinical Course and Prognostic Factors in Nigeria | — | Alliance for International Medical Action | ACTIVE_NOT_RECRUITING |
[NCT07419373](https://clinicaltrials.gov/study/NCT07419373) | ARN-75039 Lassa Fever Treatment in West Africa | PHASE2 | Arisan Therapeutics, Inc. | UNKNOWN |
234 publications have been identified in PubMed for Lassa fever. Research spans Epidemiology / Natural History (30%), Basic Science / Preclinical (26%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 71 | 30% |
Laboratory research | 60 | 26% |
Research summaries | 32 | 14% |
Patient case studies | 18 | 8% |
New treatment approaches | 16 | 7% |
Testing and diagnosis research | 15 | 6% |
Clinical study results | 13 | 6% |
Other research | 9 | 4% |
Ortiz JR (2026). [PMID: 42265408](https://pubmed.ncbi.nlm.nih.gov/42265408/). *Nat Med*. [Clinical Trial Publication]
Ko M (2026). [PMID: 42114649](https://pubmed.ncbi.nlm.nih.gov/42114649/). *Int J Infect Dis*. [Epidemiology / Natural History]
Casel MAB (2026). [PMID: 42090821](https://pubmed.ncbi.nlm.nih.gov/42090821/). *Curr Opin Virol*. [Review / Meta-Analysis]
Camara J (2026). [PMID: 42116668](https://pubmed.ncbi.nlm.nih.gov/42116668/). *Emerg Infect Dis*. [Epidemiology / Natural History]
Schafer AM (2026). [PMID: 41884425](https://pubmed.ncbi.nlm.nih.gov/41884425/). *Open Forum Infect Dis*. [Epidemiology / Natural History]
Erameh C (2026). [PMID: 42141199](https://pubmed.ncbi.nlm.nih.gov/42141199/). *Nat Med*. [Clinical Trial Publication]
Wohl DA (2026). [PMID: 41519139](https://pubmed.ncbi.nlm.nih.gov/41519139/). *The Lancet. Infectious diseases*. [Case Report / Case Series]
Lindsley IC (2026). [PMID: 42149938](https://pubmed.ncbi.nlm.nih.gov/42149938/). *PLoS Negl Trop Dis*. [Epidemiology / Natural History]
Qureshi AA (2026). [PMID: 42254098](https://pubmed.ncbi.nlm.nih.gov/42254098/). *Ann Med Surg (Lond)*. [Other]
Bansal A (2026). [PMID: 41519823](https://pubmed.ncbi.nlm.nih.gov/41519823/). *Systematic reviews*. [Review / Meta-Analysis]
AI-curated news mentioning Lassa fever
Updated Oct 28, 2024
The CDC and Iowa Department of Health are investigating a suspected case of Lassa fever in an Iowa resident who recently returned from West Africa. This highlights ongoing public health concerns regarding infectious diseases and travel.
A U.S. traveler returning from Liberia has died from Lassa fever, as confirmed by the CDC and the New Jersey Department of Health. This incident highlights the ongoing risks associated with this viral hemorrhagic fever.
A traveler returning from West Africa has been diagnosed with Lassa fever in Minnesota, confirmed by the CDC. The patient, who exhibited symptoms of fever and confusion, is currently recovering and in stable condition.